214 related articles for article (PubMed ID: 36700229)
1. The frequency of differentiated CD3
Worel N; Grabmeier-Pfistershammer K; Kratzer B; Schlager M; Tanzmann A; Rottal A; Körmöczi U; Porpaczy E; Staber PB; Skrabs C; Herkner H; Gudipati V; Huppa JB; Salzer B; Lehner M; Saxenhuber N; Friedberg E; Wohlfarth P; Hopfinger G; Rabitsch W; Simonitsch-Klupp I; Jäger U; Pickl WF
Front Immunol; 2022; 13():1004703. PubMed ID: 36700229
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
3. Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
Li C; Zhou F; Wang J; Chang Q; Du M; Luo W; Zhang Y; Xu J; Tang L; Jiang H; Liu L; Kou H; Lu C; Liao D; Wu J; Wei Q; Ke S; Deng J; Liu C; Mei H; Hu Y
J Hematol Oncol; 2023 Jan; 16(1):5. PubMed ID: 36681817
[TBL] [Abstract][Full Text] [Related]
4. Impaired Upregulation of the Costimulatory Molecules, CD27 and CD28, on CD4
Tanaskovic S; Price P; French MA; Fernandez S
AIDS Res Hum Retroviruses; 2017 Feb; 33(2):101-109. PubMed ID: 27701900
[TBL] [Abstract][Full Text] [Related]
5. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
Wada F; Jo T; Arai Y; Kitawaki T; Mizumoto C; Kanda J; Nishikori M; Yamashita K; Nagao M; Takaori-Kondo A
Sci Rep; 2022 Nov; 12(1):18696. PubMed ID: 36333521
[TBL] [Abstract][Full Text] [Related]
6. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
[TBL] [Abstract][Full Text] [Related]
7. CXCR5
Tang J; Zha J; Guo X; Shi P; Xu B
Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
9. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
[TBL] [Abstract][Full Text] [Related]
11. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.
El-Galaly TC; Cheah CY; Kristensen D; Hutchison A; Hay K; Callréus T; Villa D
Acta Oncol; 2020 Jul; 59(7):766-774. PubMed ID: 32189546
[No Abstract] [Full Text] [Related]
12. Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy.
Hou H; Luo Y; Tang G; Zhang B; Ouyang R; Wang T; Huang M; Wu S; Li D; Wang F
Cancer Cell Int; 2021 May; 21(1):282. PubMed ID: 34044841
[TBL] [Abstract][Full Text] [Related]
13. Characterization of senescence biomarkers in rheumatoid arthritis: relevance to disease progression.
Petersen LE; Schuch JB; de Azeredo LA; Baptista TSA; Motta JG; do Prado AD; Bauer ME
Clin Rheumatol; 2019 Oct; 38(10):2909-2915. PubMed ID: 31187337
[TBL] [Abstract][Full Text] [Related]
14. Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
Dubnikov Sharon T; Assayag M; Avni B; Kfir-Erenfeld S; Lebel E; Gatt ME; Goldschmidt N; Stepensky P; Asherie N; Grisariu S
Br J Haematol; 2023 Jul; 202(1):74-85. PubMed ID: 37070396
[TBL] [Abstract][Full Text] [Related]
15. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
17. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
18. [Immunological monitoring of the efficacy of extracorporeal photopheresis for prevention of kidney transplant rejection].
Faenko AP; Chuksina YY; Zulkarnayev AB; Fedulkina VA; Vatazin AV; Kantaria RO
Urologiia; 2020 Sep; (4):73-78. PubMed ID: 32897018
[TBL] [Abstract][Full Text] [Related]
19. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Olson K; Rizvi S; Fiaschi N; Coetzee S; Wang F; Ullman E; Ahmed HS; Herlihy E; Lee K; Havel L; Potocky T; Ebstein S; Frleta D; Khatri A; Godin S; Hamon S; Brouwer-Visser J; Gorenc T; MacDonald D; Hermann A; Chaudhry A; Sirulnik A; Olson W; Lin J; Thurston G; Lowy I; Murphy AJ; Smith E; Jankovic V; Sleeman MA; Skokos D
Sci Transl Med; 2022 Nov; 14(670):eabn1082. PubMed ID: 36350988
[TBL] [Abstract][Full Text] [Related]
20. [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].
Ren CX; Chen XX; Zhao L; Tian Y; Xu KL; Zhao K
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):506-512. PubMed ID: 35968595
[No Abstract] [Full Text] [Related]
[Next] [New Search]
